MLTX vs. ACAD, MOR, EVO, SMMT, IDYA, JANX, INDV, ARWR, CRNX, and XENE
Should you be buying MoonLake Immunotherapeutics stock or one of its competitors? The main competitors of MoonLake Immunotherapeutics include ACADIA Pharmaceuticals (ACAD), MorphoSys (MOR), Evotec (EVO), Summit Therapeutics (SMMT), IDEAYA Biosciences (IDYA), Janux Therapeutics (JANX), Indivior (INDV), Arrowhead Pharmaceuticals (ARWR), Crinetics Pharmaceuticals (CRNX), and Xenon Pharmaceuticals (XENE). These companies are all part of the "pharmaceutical preparations" industry.
MoonLake Immunotherapeutics (NASDAQ:MLTX) and ACADIA Pharmaceuticals (NASDAQ:ACAD) are both mid-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, analyst recommendations, community ranking, valuation, dividends and media sentiment.
MoonLake Immunotherapeutics presently has a consensus price target of $74.46, indicating a potential upside of 75.20%. ACADIA Pharmaceuticals has a consensus price target of $35.82, indicating a potential upside of 116.59%. Given ACADIA Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe ACADIA Pharmaceuticals is more favorable than MoonLake Immunotherapeutics.
MoonLake Immunotherapeutics has a net margin of 0.00% compared to ACADIA Pharmaceuticals' net margin of -8.44%. MoonLake Immunotherapeutics' return on equity of -9.22% beat ACADIA Pharmaceuticals' return on equity.
MoonLake Immunotherapeutics has a beta of 1.2, indicating that its share price is 20% more volatile than the S&P 500. Comparatively, ACADIA Pharmaceuticals has a beta of 0.37, indicating that its share price is 63% less volatile than the S&P 500.
MoonLake Immunotherapeutics has higher earnings, but lower revenue than ACADIA Pharmaceuticals. MoonLake Immunotherapeutics is trading at a lower price-to-earnings ratio than ACADIA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
In the previous week, ACADIA Pharmaceuticals had 5 more articles in the media than MoonLake Immunotherapeutics. MarketBeat recorded 10 mentions for ACADIA Pharmaceuticals and 5 mentions for MoonLake Immunotherapeutics. MoonLake Immunotherapeutics' average media sentiment score of 0.64 beat ACADIA Pharmaceuticals' score of -0.09 indicating that MoonLake Immunotherapeutics is being referred to more favorably in the media.
ACADIA Pharmaceuticals received 826 more outperform votes than MoonLake Immunotherapeutics when rated by MarketBeat users. However, 76.27% of users gave MoonLake Immunotherapeutics an outperform vote while only 73.07% of users gave ACADIA Pharmaceuticals an outperform vote.
93.9% of MoonLake Immunotherapeutics shares are owned by institutional investors. Comparatively, 96.7% of ACADIA Pharmaceuticals shares are owned by institutional investors. 15.3% of MoonLake Immunotherapeutics shares are owned by insiders. Comparatively, 27.5% of ACADIA Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Summary
ACADIA Pharmaceuticals beats MoonLake Immunotherapeutics on 10 of the 17 factors compared between the two stocks.
Get MoonLake Immunotherapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for MLTX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MLTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
MoonLake Immunotherapeutics Competitors List
Related Companies and Tools
